




RealRate

PHARMACEUTICAL 2022

EYENOVIA INC. Rank 264 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2022

EYENOVIA INC. Rank 264 of 475



The relative strengths and weaknesses of EYENOVIA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EYENOVIA INC. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 157% points. The greatest weakness of EYENOVIA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -137%, being 139% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	22,002
Cost of Goods Sold	1,600
Intangible Assets	0
Liabilities, Current	11,172
Liabilities, Non-Current	0
Other Assets	8,386
Other Compr. Net Income	0
Other Expenses	388
Other Liabilities	20
Other Net Income	513
Property and Equipment	1,271
Research and Development	14,510
Revenues	14,000
Selling, General and Administrative Expense	10,794

Output Variable	Value in 1000 USD
Assets	31,659
Liabilities	11,192
Expenses	27,291
Stockholders Equity	20,467
Net Income	-12,778
Comprehensive Net Income	-12,778
Economic Capital Ratio	-137%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai